Cancer pathology: adapting to and advancing with immunotherapy

In this interview, Manuel Salto-Tellez, MD (LMS), FRCPath, FRCPI, from Queen's University Belfast, Belfast, UK, discusses the changing landscape of cancer pathology as a result of cancer immunotherapy. Prof. Salto-Tellez reveals the key paradigms surrounding the use of biomarkers, stressing the improvements needed in the prediction of response to a drug. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.